QR Code

Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system

Show other versions (1)

Saved in:

Bibliographic Details
Main Authors:	Wangqi Chen, Yuxia Xie, Qinghua Li, Zhenghui Zhu, Xinyan Li, Hong Zhu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262908/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system.
by: Wangqi Chen, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for etoricoxib used in arthritis
by: Wenjun Cai, et al.
Published: (2025-07-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)

Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Xinzhen Che, et al.
Published: (2025-06-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics
by: Wangqi Chen, et al.
Published: (2025-08-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database
by: Yaxin Ju, et al.
Published: (2025-07-01)

Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study.
by: Yuting Chen, et al.
Published: (2025-01-01)

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
by: Jingkai Di, et al.
Published: (2025-07-01)

Incidence of Adverse Events Related to Therapies with sodium iodine (131I): Contribution to the Pharmacovigilance in Brazil
by: Jaqueline Cardena Fernandes, et al.
Published: (2024-09-01)

Investigation into Safety Profiles of Antiepileptic Drugs and Identification of Predictors for Serious Adverse Events: Insights from National Pharmacovigilance Data
by: Soo Hyeon Lee, et al.
Published: (2025-07-01)

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
by: Hilal A. Thaibah, et al.
Published: (2025-06-01)

Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Lin Y, et al.
Published: (2025-06-01)

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
by: Akimasa Sanagawa, et al.
Published: (2018-06-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Potential adverse events of fluoxetine: a real-world study based on the FAERS database
by: Xuezheng Gao, et al.
Published: (2025-07-01)

Signal Management: Updated Requirements of the EAEU Good Pharmacovigilance Practice
by: A. V. Matveev, et al.
Published: (2023-03-01)

Pharmacovigilance-related events, disease burden and overall efficiency of care in european countries, 1990-2021
by: Lin Yin, et al.
Published: (2025-06-01)

Hypoparathyroidism induced by immune checkpoint inhibitors: a review of literature reports and real-world pharmacovigilance data
by: Jiaxun Jiao, et al.
Published: (2025-07-01)

Application of the bile duct tree concept in minimally invasive surgery for intrahepatic bile duct stones
by: LI Jingdong, HUANG Xujian, LI Qiang, ZHU Jianjiao
Published: (2025-03-01)

Adverse Reactions to Intravenous Immunoglobulin Therapy: An Analysis of the Russian National Pharmacovigilance Database
by: A. V. Nechaev, et al.
Published: (2024-12-01)

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)

AI-driven pharmacovigilance: Enhancing adverse drug reaction detection with deep learning and NLP
by: Dr. Bharti Khemani, et al.
Published: (2025-12-01)

Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson’s Disease Treatment
by: Jungmin Han, et al.
Published: (2025-06-01)

Signal mining and risk analysis of olanzapine adverse events in the FAERS database
by: Aiguo Dong, et al.
Published: (2025-07-01)

Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024)
by: Hassan Aliashrafzadeh, et al.
Published: (2025-07-01)

Organisation of the Russian Pharmacovigilance System: Survey of Pharmacovigilance Officers
by: A. E. Krasheninnikov, et al.
Published: (2021-10-01)

ON THE SUBJECT OF PHARMACOVIGILANCE
by: M. A. Murashko
Published: (2015-09-01)